Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
|Articles|July 5, 2018
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
Author(s)Michelle Maskaly
New Jersey is still a top pick for companies when it comes to pharma.
Advertisement
Ki-Young Sohn, chairman and CEO of Enzychem Lifesciences, explains why the company selected New Jersey as the location for their U.S. offices.
He spoke to Pharm Exec during a company event in New York City.
Advertisement
Related to this article
Pharma AI adoption fails not because of the technology — but because organizations deploy tools before they're ready to use them.
As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Before You Sign with a New Hub Vendor, Ask These Four Questions
4
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
5